Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

The treatment guidelines for non-muscle-invasive bladder cancer (NMIBC) consist of endoscopic resection of the tumor, then administration of drugs into the bladder (intravesical therapy), typically ...

The administration of immediate instillation of intravesical chemotherapy (IVCT) following transurethral resection of bladder tumour (TURBT) has been shown to decrease the risk of recurrence and is ...

IBCN annual meeting included a bladder cancer session, featuring a presentation by Dr. Amanda Myers discussing the ...

Immvira Group Co.’s oncolytic herpes simplex virus product, MVR-T3011, showed early efficacy via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer.

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of ...

Let’s learn about the various types of cancer, their symptoms, causes, and treatment options, as well as about common cancers ...

The following is a summary of “External validation demonstrates machine learning models outperform human experts in prediction of objective and patient-reported overactive bladder treatment outcomes,” ...